Total Payments
$2,663
2024 Payments
$282.29
Companies
12
Transactions
153
Medicare Patients
372
Medicare Billing
$70,021
Payment Breakdown by Category
Food & Beverage$2,616 (98.2%)
Education$46.91 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,616 | 152 | 98.2% |
| Education | $46.91 | 1 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $835.24 | 52 | $0 (2024) |
| ITI, Inc. | $334.08 | 17 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $254.78 | 13 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $239.63 | 14 | $0 (2022) |
| Lundbeck LLC | $232.79 | 15 | $0 (2024) |
| Alkermes, Inc. | $224.27 | 10 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $203.19 | 15 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $136.98 | 7 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $112.76 | 5 | $0 (2022) |
| Corium, LLC | $55.53 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $282.29 | 17 | ABBVIE INC. ($182.58) |
| 2023 | $479.76 | 31 | Teva Pharmaceuticals USA, Inc. ($164.31) |
| 2022 | $493.17 | 22 | ABBVIE INC. ($217.99) |
| 2021 | $1,408 | 83 | ITI, Inc. ($300.76) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $90.88 | General |
| Category: NEUROSCIENCE | ||||||
| 12/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.19 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.20 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.48 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.45 | General |
| Category: NEUROSCIENCE | ||||||
| 07/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.80 | General |
| Category: NEUROSCIENCE | ||||||
| 06/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.94 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Neurology | ||||||
| 04/30/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.51 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.62 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Neuroscience | ||||||
| 02/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: NEUROSCIENCE | ||||||
| 02/22/2024 | Sage Therapeutics, Inc. | ZURZUVAE (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: PSYCHIATRY/PSYCHOLOGY | ||||||
| 01/23/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Neuroscience | ||||||
| 12/07/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $31.89 | General |
| Category: Central Nervous System | ||||||
| 12/05/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: NEUROSCIENCE | ||||||
| 11/30/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Central Nervous System | ||||||
| 11/02/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: Central Nervous System | ||||||
| 11/02/2023 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: Central Nervous System | ||||||
| 10/26/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 2 | 123 | 340 | $37,080 | $26,906 |
| 2020 | 4 | 249 | 566 | $61,061 | $43,116 |
Total Patients
372
Total Services
906
Medicare Billing
$70,021
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 110 | 324 | $35,960 | $25,911 | 72.1% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 13 | 16 | $1,120 | $994.24 | 88.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 185 | 496 | $55,135 | $38,028 | 69.0% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 18 | 19 | $2,090 | $2,090 | 100.0% |
| 80307 | Testing for presence of drug | Office | 2020 | 28 | 33 | $2,310 | $2,044 | 88.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 18 | $1,526 | $952.96 | 62.4% |
About Pamela Matthews
Pamela Matthews is a Psychiatric/Mental Health healthcare provider based in Bourne, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2018. The National Provider Identifier (NPI) number assigned to this provider is 1558852301.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Pamela Matthews has received a total of $2,663 in payments from pharmaceutical and medical device companies, with $282.29 received in 2024. These payments were reported across 153 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($2,616).
As a Medicare-enrolled provider, Matthews has provided services to 372 Medicare beneficiaries, totaling 906 services with total Medicare billing of $70,021. Data is available for 2 years (2020–2021), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatric/Mental Health
- Other Specialties Adult
- Location Bourne, MA
- Active Since 05/27/2018
- Last Updated 06/05/2023
- Taxonomy Code 363LP0808X
- Entity Type Individual
- NPI Number 1558852301
Products in Payments
- VRAYLAR (Drug) $835.24
- CAPLYTA (Drug) $334.08
- LATUDA (Drug) $254.78
- REXULTI (Drug) $157.91
- BRINTELLIX (Drug) $141.66
- INVEGA SUSTENNA (Drug) $136.98
- ARISTADA (Drug) $119.70
- TRINTELLIX (Drug) $112.76
- ABILIFY MAINTENA (Drug) $111.51
- Austedo XR (Drug) $106.40
- LYBALVI (Drug) $104.57
- AUSTEDO (Drug) $80.03
- ABILIFY MYCITE (Drug) $61.34
- Azstarys (Drug) $55.53
- ZURZUVAE (Drug) $20.33
- UZEDY (Drug) $16.76
- QELBREE (Drug) $13.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.